Bausch + Lomb (BLCO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
Q3 revenue was $1.375B, up 7% reported and 8% at constant currency; adjusted EBITDA rose 34% to $325M and all three segments grew.
Full-year 2026 revenue and adjusted EBITDA guidance increased on Q3 strength and an improved outlook for the remainder of the year.
Performance marked a fourth consecutive quarter meeting Investor Day commitments; interim CEO priorities include profitability, efficiency, disciplined innovation investment and Vision 2027 targets.
Financial highlights
Q3 revenue rose $94M YoY; volume added $63M and pricing $31M, partly offset by $6M of FX headwind and $2M from divestitures and discontinuations.
GAAP operating income was $155M versus $95M; attributable net income was $32M versus a $28M loss, and adjusted net income was $123M versus $66M.
Adjusted gross margin increased 300 bps to 64.7%, including a one-time ~$14M tariff refund; excluding the refund, margin was 63.6%.
Q3 operating cash flow was $233M and free cash flow was $178M after $55M of capex; 9M operating cash flow reached $418M.
Outlook and guidance
FY26 revenue guidance rose to $5.450B–$5.550B, with constant-currency growth of 6.1%–8.0%; underlying outlook increased $15M, partly offset by $5M lower FX tailwinds.
FY26 adjusted EBITDA guidance increased $65M to $1.090B–$1.140B; midpoint implies ~20.3% margin and 25% growth.
FY26 assumptions include adjusted gross margin of 62.5%–63.0%, net interest expense of ~$365M, adjusted tax rate of ~18% and capex of ~$285M.
Management remains focused on meeting or exceeding three-year Investor Day targets; the 2028 adjusted EBITDA margin target is 23%.
Latest events from Bausch + Lomb
- FY23 growth broadened across segments as margin pressure and supply disruption persisted.BLCO
Q4 2023 - Dual-action dry eye and BL1332 pain therapies show rapid efficacy, safety, and $2B+ peak sales potential.BLCO
Study result - Q2 2026 delivered 9% revenue growth, margin expansion, and raised full-year guidance.BLCO
Q2 2026 - Operational excellence and breakthrough innovation drive growth and margin expansion through 2028.BLCO
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Bioactive and myopia control lenses target 2028–2029 launches, with peak sales up to $500M.BLCO
R&D Day 2026 - All proposals voted on were approved, with final results to be filed in a Form 8-K.BLCO
AGM 2026 - Q1 2026 revenue up 9%, adjusted EBITDA up 59%, and full-year guidance raised.BLCO
Q1 2026 - BL1107 and ELIOS advance as innovative glaucoma solutions, targeting major unmet needs.BLCO
Status update - Q3 2025 revenue rose 7% to $1.281B, with strong segment growth and $28M net loss.BLCO
Q3 2025